Navigation Links
Cappella Promotes Sideguard & Serial IVUS Analysis at JIM 2010
Date:2/19/2010

GALWAY, Ireland, Feb. 19 /PRNewswire/ -- Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, promoted their serial IVUS analysis & Sideguard® 3.25 device during the Joint Interventional Meeting (JIM) in Rome. Gary S. Mintz, MD, Cardiovascular Research Foundation, New York, USA presented "Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations" during the New Technologies 1 Symposium. Dr. Mintz highlighted that serial IVUS & OCT are ongoing in the Sideguard 3 study to confirm the initial findings of Sideguard 1 and assess stent strut coverage. The IVUS sub-study results from Sideguard 1 were published in the American Journal of Cardiology in October 2009.

The newest addition to the Sideguard portfolio, the Sideguard 3.25, was implanted successfully in a live case performed by Ralf Mueller, MD, Siegburg, Germany. According to Dr. Mueller, "We implanted the Sideguard 3.25 stent together with a 3,0mm DES in a Medina 0,1,1 LAD/D1 stenosis.  Positioning was easy and precise and IVUS demonstrated excellent scaffolding at the bifurcation. The use of the Sideguard device made this bifurcation intervention easy and predictable with an optimal acute result."

Martin B. Leon, MD, Founder & Director of Transcatheter Cardiovascular Therapeutics (TCT) and Scientific Advisory Board member of Cappella assisted with the case. Dr. Leon expressed his satisfaction with the device, "It was the first time I used the 3.25 & I was very pleased with the outcome of the case."

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. More importantly, it allows the preferred stent of choice for the main vessel. An optimal stent design specific to the anatomy of the sidebranch, combined with the qualities of Nitinol now provide a dynamic solution for treating sidebranch disease. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc.  For more information, see: www.cappella-med.com.

SOURCE Cappella Inc.

Back to top

RELATED LINKS
http://www.cappella-med.com

'/>"/>

SOURCE Cappella Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Eamonn Hobbs Joins the Board of Directors at Cappella
2. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
3. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
4. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
5. PLAN C Agency Promotes Hepatitis B Awareness Through B HERE
6. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
7. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
8. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
9. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
10. Robbins & Myers Announces Regular Quarterly Cash Dividend
11. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an ... passed early toxicology and efficacy studies. The company is ... a specific protein, MAGE A, in an effort to ... After 4 weeks of treatment in ... very little toxicity in a full toxicology report of ...
(Date:3/27/2017)... 27, 2017 To mark the end of Save ... a leader in digital imaging solutions, will showcase Canon eye ... at New York,s Jacob Javits Center ... Month, sponsored by the American Optometric Association, is observed annually ... receiving comprehensive eye exams. In recognition of this observance, Canon ...
(Date:3/27/2017)... 27, 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s ... where cannabis is legal will generate $655 million in taxes on ... cannabis specific taxes, such as Washington State,s ... earned from state sales taxes that are applied on all retail ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... The respected dental team at ... teeth without the extensive time commitment and aesthetic disadvantages of traditional braces can ... A custom-designed series of virtually invisible aligners are created for each patient and ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to ... missing teeth can now have them placed by Dr. Manju Kejriwal, with or without ... Beam technology to increase the accuracy of each dental implant placement. The i-CAT CBCT ...
(Date:3/27/2017)... UK (PRWEB) , ... March 27, 2017 , ... ... and ability to gain site attention and engagement over the household brands of ... webinar will discuss how partnering with the right outsourcing payments provider ...
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the ... and his colleague, Sudeep Roy, MD, was recently published in the American Journal ... in Rhytidectomy” details Drs. Buckingham and Roy’s study on the use of Electro Lube ...
(Date:3/27/2017)... ... ... Buzzies parent company, The TouchPoint Solution’s CEO and co-founder, Vicki Mayo, was recently ... Mayo will present her pitch about the lifestyle wearable devices, Buzzies live ... ignites bold ideas by providing women access to the tools, training and networks needed ...
Breaking Medicine News(10 mins):